Correspondingly, the metformin monotherapy failed to significantly prolong the survival of CML CD34+ cell transplanted mice, whereas the combination of metformin with imatinib effectively retarded the engraftment of human CD34+ stem/progenitor cells, leading to significantly longer survival (Fig. 5D). This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.